The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) Hypothesis: A novel postulate to understand schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 301-311

  Venkatasubramanian, Ganesan ^a   Debnath, Monojit ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Inflammation; Microglia; Neurodegeneration; Oxidative nitrosative stress; Schizophrenia; Toll like receptors

Indexed keywords

REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4;

APOPTOSIS; BRAIN DEVELOPMENT; CELL SURVIVAL; EMBRYO DEVELOPMENT; HUMAN; HYPOTHESIS; IMMUNITY; INFLAMMATION; INTRAUTERINE INFECTION; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TOLL LIKE RECEPTORS IN IMMUNOINFLAMMATORY PATHOGENESIS HYPOTHESIS;

ANIMALS; ENVIRONMENT; HUMANS; IMMUNITY; INFLAMMATION; MODELS, BIOLOGICAL; SCHIZOPHRENIA; TOLL-LIKE RECEPTORS;

EID: 84877325936     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.001     Document Type: Review

References (204)

1. Abrahams V.M., Bole-Aldo P., Kim Y.M., et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 2004, 173:4286-4296.
2. Abrahams V.M., Fahey J.V., Schaefer T.M., Wright J.A., Wira C.R., Mor G. Stimulation of first trimester trophoblast cells with Poly(I:C) induces SLPI secretion. Am J Reprod Immunol 2005, 53:280.
3. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
4. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
5. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 2004, 10:S18-S25.
6. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:101-114.
7. Anderson G., Berk M., Dodd S., Bechter K., Altamura A.C., Dell'osso B., et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:1-4.
8. Arrode-Bruses G., Bruses J.L. Maternal immune activation by poly(I:C) induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflammation 2012, 9:83.
9. Arroyo D.S., Soria J.A., Gaviglio E.A., Rodriguez-Galan M.C., Iribarren P. Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 2011, 11:1415-1421.
10. Asehnoune K., Strassheim D., Mitra S., Kim J.Y., Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004, 172:2522-2529.
11. Ashdown H., Dumont Y., Ng M., Poole S., Boksa P., Luheshi G.N. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 2006, 11:47-55.
12. Ashe P.C., Berry M.D., Boulton A.A. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:691-707.
13. Barak V., Barak Y., Levine J., Nisman B., Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 1995, 6:61-69.
14. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440.
15. Bechter K. Updating the mild encephalitis hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:71-91.
16. Behrens M.M., Sejnowski T.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharmacology 2009, 57:193-200.
17. Beijar E.C.E., Mallard C., Powell T.L. Expression and subcellular localization of TLR-4 in term and first trimester human placenta. Placenta 2006, 27:322-326.
18. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009, 12:441-445.
19. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 2012, 92:959-975.
20. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35:878-893.
21. Borda T., Gomez R., Berria M.I., Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 2004, 45:144-154.
22. Boska P. Effects of prenatal infection on brain development and behaviour: a review of findings from animal models. Brain Behav Immun 2010, 24:881-897.
23. Bošković M., Vovk T., Kores Plesničar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9:301-312.
24. Brown A.S. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011, 93:23-58.
25. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
26. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011, 37:284-290.
27. Bsibsi M., Ravid R., Gveric D., Van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002, 61:1013-1021.
28. Busse S., Busse M., Schiltz K., Bielau H., Gos T., Brisch R., et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behav Immun 2012, 26:1273-1279.
29. Carpentier P.A., Dingman A.L., Palmer T.D. Placental TNF-α signaling in illness-induced complications of pregnancy. Am J Pathol 2011, 178:2802-2810.
30. Carter C.J. Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes. J Pathog 2011, 2011:128318.
31. Chang S.H., Chiang S.Y., Chiu C.C., Tsai C.C., Tsai H.H., Huang C.Y., et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res 2011, 187:341-346.
32. Chatterjee P., Weaver L.E., Doersch K.M., Kopriva S.E., Chiasson V.L., et al. Placental toll-like receptor 3 and toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One 2012, 7:e41884.
33. Chaudhry I.B., Hallak J., Husain N., Minhas F.A., Stirling J., Richardson P., et al. Minocycline benefits symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012, 26:1185-1193.
34. Cunningham C., Campion S., Lunnon K., Murray C.L., Woods J.F., Deacon R.M., et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009, 65:304-312.
35. Dalman C., Allebeck P., Cullberg J., Grunewald C., Koster M. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 1999, 56:234-240.
36. Dalmau J., Gleichman A.J., Hughes E.G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
37. De Miranda J., Yaddanapudi K., Hornig M., Villar G., Serge R., Lipkin W.I. Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances. mBio 2010, 1:e00176-e.
38. Debnath M., Chaudhuri T.K. The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: a novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med Hypotheses 2006, 66:286-293.
39. Debnath M., Doyle K.M., Langan C., McDonald C., Leonard B., Cannon D.M. Recent advances in psychoneuroimmunology: inflammation in psychiatric disorder. Transl Neurosci 2011, 2:121-137.
40. Debnath M., Cannon D.M., Venkatasubramanian G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:49-62.
41. DeLisi L.E. Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later. Schizophr Res 1996, 22:1-4.
42. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008, 34:312-321.
43. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009, 19:220-230.
44. Doorduin J., de Vries E.F.J., Willemsen A.T.M., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009, 50:1801-1807.
45. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010, 13:1369-1381.
46. Drexler S.K., Foxwell B.M. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010, 42:506-518.
47. Du X., Fleiss B., Li H., D'angelo B., Sun Y., et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One 2011, 6:e19583.
48. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006, 163:521-528.
49. Esch T., Stefano G.B., Fricchione G.L., Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol Lett 2002, 23:199-208.
50. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35:528-548.
51. Field R., Campion S., Warren C., Murray C., Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010, 24:996-1007.
52. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013, 18:206-214.
53. Forrest C.M., Khalil O.S., Pisar M., Smith R.A., Darlington L.G., Stone T.W. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-d-aspartate receptors and neurogenesis markers in offspring. Mol Brain 2012, 5:22.
54. Ganguli R., Brar J.S., Roy Chengappa K.N., Yang Z.W., Nimgaonkar V.L., Rabin B.S. Autoimmunity in schizophrenia: a review of recent findings. Ann Med 1993, 25:489-496.
55. Ganguli R., Brar J.S., Rabin B.S. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv Rev Psychiatry 1994, 2:70-83.
56. Garay P.A., McAllister A.K. Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci 2010, 2:1-16.
57. Garay P.A., Hsiao E.Y., Patterson P.H., McAllister A.K. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav Immun 2013, [in press].
58. Gill R., Tsung A., Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010, 48:1121-1132.
59. Gilmore J.H., Jarskog L.F. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res 1997, 24:365-367.
60. Gilmore J.H., Fredrik Jarskog L., Vadlamudi S., Lauder J.M. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29:1221-1229.
61. Gispen-de Wied C.C. Stress in schizophrenia: an integrative view. Eur J Pharmacol 2000, 405:375-384.
62. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 72:1493-1505.
63. Goldsmith C.A., Rogers D.P. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy 2008, 28:730-741.
64. Gonzalez J.M., Xu H., Ofori E., Elovitz M.A. Toll-like receptors in the uterus, cervix, and placenta: is pregnancy an immunosuppressed state?. Am J Obstet Gynecol 2007, 197:296.e1-296.e6.
65. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A 2007, 104:16621-16626.
66. Hagberg H., Gressens P., Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012, 71:444-457.
67. Hanke M.L., Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci 2011, 121:367-387.
68. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 1994, 14:15-22.
69. Herberth M., Rahmoune H., Schwarz E., Koethe D., Harris L.W., Kranaster L., et al. Identification of a molecular profile associated with immune status in first onset schizophrenia patients. Clin Schizophr Relat Psychoses 2013, 8:1-14.
70. Hsiao E.Y., Patterson P.H. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun 2011, 25:604-615.
71. Hutton L.C., Castillo-Melendez M., Smythe G.A., Walker D.W. Microglial activation, macrophage infiltration, and evidence of cell death in the fetal brain after uteroplacental administration of lipopolysaccharide in sheep in late gestation. Am J Obstet Gynecol 2008, 198:117.e1-117.e11.
72. Ikonomidou C., Kaindl A.M. Neuronal death and oxidative stress in the developing brain. Antioxid Redox Signal 2011, 14:1535-1550.
73. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
74. Janssen-Heininger Y.M., Poynter M.E., Baeuerle P.A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor-kB. Free Radic Biol. Med. 2000, 28:1317.
75. Jhamnani K., Shivakumar V., Kalmady S., Rao N.P., Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2013, 25:E06-E07.
76. Jonakait G. The effects of maternal inflammation on neuronal development: possible mechanisms. Int J Dev Neurosci 2007, 25:415-425.
77. Jones S.R., Fernyhough C. A new look at the neural diathesis-stress model of schizophrenia: the primacy of social-evaluative and uncontrollable situations. Schizophr Bull 2007, 33:1171-1177.
78. Juckel G., Manitz M.P., Brüne M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res 2011, 131:96-100.
79. Jung D.Y., Lee H., Jung B.Y., Ock J., Lee M.S., Lee W.H., et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-β as a decision maker. J Immunol 2005, 174:6467-6476.
80. Kacimi R., Giffard R.G., Yenari M.A. Endotoxin-activated microglia injure brain derived endothelial cells via NF-κB, JAK-STAT and JNK stress kinase pathways. J Inflamm 2011, 8:7.
81. Kaul D., Habbel P., Derkow K., Krüger C., Franzoni E., et al. Expression of Toll-like receptors in the developing brain. PLoS One 2012, 7:e37767.
82. Kaur C., Rathnasamy G., Ling E.A. Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina. J Neuroimmune Pharmacol 2013, 8:66-78.
83. Kawai T., Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7:131-137.
84. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19:24-32.
85. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
86. Kayser M.S., Kohler C.G., Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010, 167:1039-1050.
87. Kayser M.S., Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011, 23:90-97.
88. Khandaker G.M., Zimbron J., Lewis G., Jones P.B. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 2012, 16:1-19.
89. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 1993, 19:355-370.
90. Koga K., Mor G. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am J Reprod Immunol 2010, 63:587-600.
91. Kong Y., Le Y. Toll-like receptors in inflammation of the central nervous system. Int Immunopharmacol 2011, 11:1407-1414.
92. Krause D.L., Wagner J.K., Wildenauer A., Matz J., Weidinger E., Riedel M., et al. Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6. Eur Arch Psychiatry Clin Neurosci 2012, 262:393-401.
93. Krause D., Wagner J., Matz J., Weidinger E., Obermeier M., Riedel M., et al. Monocytic HLA DR antigens in schizophrenic patients. Neurosci Res 2012, 72:87-93.
94. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1677-1681.
95. Lafon M., Megret F., Lafage M., et al. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci 2006, 29:185-194.
96. Lante F., Meunier J., Guiramand J., Maurice T., Cavalier M., et al. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radic Biol Med 2007, 42:1231-1245.
97. Larsen P.H., Holm T.H., Owens T. Toll-like receptors in brain development and homeostasis. Sci STKE 2007, 402:pe47.
98. Lathia J.D., Okun E., Tang S.C., Griffioen K., Cheng A., Mughal M.R., et al. Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. J Neurosci 2008, 28:13978-13984.
99. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009, 1:a001651.
100. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
101. Lehnardt S., Lachance C., Patrizi S., Lefebvre S., Follett P.L., Jensen F.E., et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002, 22:2478-2486.
102. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003, 100:8514-8519.
103. Lennox B.R., Coles A.J., Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012, 200:92-94.
104. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
105. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci U S A 2005, 102:9936-9941.
106. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
107. Liu J., Wang X., Shigenaga M.K., Yeo H.C., Mori A., Ames B.N. Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats. FASEB J 1996, 10:1532-1538.
108. Liu B., Wang K., Gao H.M., Mandavilli B., Wang J.Y., Hong J.S. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J Neurochem 2001, 77:182-189.
109. Lucas K., Maes M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013, [in press].
110. Ma Y., Li J., Chiu I., Wang Y., Sloane J.A., Lu J., et al. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J Cell Biol 2006, 175:209-215.
111. Ma Y., Krikun G., Abrahams V.M., Mor G., Guller S. Cell type-specific expression and function of toll-like receptors 2 and 4 in human placenta: implications in fetal infection. Placenta 2007, 28:1024-1031.
112. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995, 29:141-152.
113. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
114. Maino K., Gruber R., Riedel M., Seitz N., Schwarz M., Müller N. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res 2007, 152:173-180.
115. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 2009, 8:285-305.
116. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835.
117. Martínez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Micó J.A., Fernandez M., Echevarría E., et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012, 137:66-72.
118. McKernan D.P., Dennison U., Gaszner G., Cryan J.F., Dinan T.G. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry 2011, 1:e36.
119. Metodiewa D., Kośka C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 2000, 1:197-3.
120. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:20-34.
121. Meyer U., Nyffeler M., Schwendener S., Knuesel I., Yee B.K., Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008, 33:441-456.
122. Miller B.J., Buckley P., Seabott W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical studies and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
123. Miller B.J., Culpepper N., Rapoport M.H., Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:92-100.
124. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009, 22:240-273.
125. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
126. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-121.
127. Moscato E.H., Jain A., Peng X., Hughes E.G., Dalmau J., Balice-Gordon R.J. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010, 32:298-309.
128. Mukherjee S., Mahadik S.P., Korenovsky A., Laev H., Schnur D.B., Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr Res 1994, 12:131-136.
129. Mukhopadhyay S., Herre J., Brown G.D., Gordon S. The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 2004, 112:521-530.
130. Müller N., Riedel M., Ackenheil M., Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 1999, 249:62-68.
131. Muller N., Wagner J.K., Krause D., Weidinger E., Wildenaurer A., Obermeier M., et al. Impaired monocyte activation in schizophrenia. Psychiatry Res 2012, 198:341-346.
132. Nguyen M.D., Julien J.P., Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nat Rev Neurosci 2002, 3:216-227.
133. Ni L., Acevedo G., Muralidharan B., Padala N., To J., Jonakait G.M. Toll-like receptor ligands and CD154 stimulate microglia to produce a factor(s) that promotes excess cholinergic differentiation in the developing rat basal forebrain: implications for neurodevelopmental disorders. Pediatr Res 2007, 61:15-20.
134. Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005, 28:886-892.
135. Nishioka N., Arnold S.E. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2004, 12:167-175.
136. Nitsos I., Rees S.M., Duncan J., Kramer B.W., Harding R., Newnham J.P., et al. Chronic exposure to intra-amniotic lipopolysaccharide affects the ovine fetal brain. J Soc Gynecol Investig 2006, 13:239-247.
137. Okun E., Griffioen K.J., Son T.G., Lee J.H., Roberts N.J., Mughal M.R., et al. TLR2 activation inhibits embryonic neural progenitor cell proliferation. J Neurochem 2010, 114:462-474.
138. Okun E., Griffioen K., Barak B., Roberts N.J., Castro K., Pita M.A., et al. Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci U S A 2010, 107:15625-15630.
139. Okun E., Griffioen K.J., Mattson M.P. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 2011, 34:269-281.
140. Okun E., Barak B., Saada-Madar R., Rothman S.M., Griffioen K.J., et al. Evidence for a developmental role for TLR4 in learning and memory. PLoS One 2012, 7:e47522.
141. Oliveira-Nascimento L., Massari P., Wetzler L.M. The role of TLR2 in infection and immunity. Front Immunol 2012, 3:79.
142. Ospelt C., Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010, 42:495-505.
143. Ospelt C., Brentano F., Rengel Y., Stanczyk J., Kolling C., Tak P.P., et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008, 58:3684-3692.
144. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006, 59:546-554.
145. Patni S., Wynen L.P., Seager A.L., Morgan G., White J.O., Thornton C.A. Expression and activity of Toll-like receptors 1-9 in the human term placenta and changes associated with labor at term. Biol Reprod 2009, 80:243-248.
146. Perlman J.M. Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin Ther 2006, 28:1353-1365.
147. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006, 40:725-741.
148. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010, 2010. [pii: 672395].
149. Pineda A., Verdin-Terán S.L., Camacho A., Moreno-Fierros L. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res 2011, 42:382-391.
150. Potvin S., Stip E., Sepehry A.A., Gendon A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
151. Qin L., Li G., Qian X., Liu Y., Wu X., Liu B., et al. Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia 2005, 52:78-84.
152. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011, 12:13.
153. Richard M.D., Brahm N.C. Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm 2012, 69:757-766.
154. Riedel M., Spellmann I., Schwarz M.J., et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 2007, 41:3-7.
155. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
156. Rolls A., Shechter R., London A., et al. Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 2007, 9:1081-1088.
157. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364.
158. Ryan K.A., Smith M.F., Sanders M.K., Ernst P.B. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect Immun 2004, 72:2123-2130.
159. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
160. Schwarz M.J., Riedel M., Gruber R., Muller N., Ackenheil M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1998, 248:282-288.
161. Shen Y., Yu H.M., Yuan T.M., Gu W.Z., Wu Y.D. Intrauterine infection induced oligodendrocyte injury and inducible nitric oxide synthase expression in developing rat brain. J Perinat Med 2007, 35:203-209.
162. Shukla V., Mishra S.K., Pant H.C. Oxidative stress in neurodegeneration. Adv Pharmacol Sci 2011, 2011. [Article ID 572634, 13 pages].
163. Sirisinha S. Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J Allergy Immunol 2011, 29:1-14.
164. Sirota P., Firer M.A., Schild K., Tanay A., Elizur A., Meytes D., et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 1993, 33:450-455.
165. Sköld A.E., Hasan M., Vargas L., Saidi H., Bosquet N., Le Grand R., et al. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012, 120:768-777.
166. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992, 39:248-257.
167. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45:135-141.
168. Smith S.E.P., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
169. Soderlund J., Schroder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., et al. Activation of brain interleukin-1b in schizophrenia. Mol Psychiatry 2009, 14:1069-1071.
170. Steelman A.J., Li J. Poly(I:C) promotes TNFα/TNFR1-dependent oligodendrocyte death in mixed glial cultures. J Neuroinflammation 2011, 8:89.
171. Steiner J., Jacobs R., Panteli B., Brauner M., Schiltz K., Bahn S., et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci 2010, 260:509-518.
172. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006, 27:71-80.
173. Sullivan E.M., O'Donnell P. Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr Bull 2012, 38:373-376.
174. Takeda K., Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9.
175. Tanaka S., Matsunaga H., Kimura M., et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003, 141:155-164.
176. Tang S.C., Arumugam T.V., Xu X., Cheng A., Mughal M.R., Jo D.G., et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007, 104:13798-13803.
177. Tsutsui K., Kanbayashi T., Tanaka K., Boku S., Ito W., Tokunaga J., et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37.
178. Urakubo A., Jarskog L.F., Lieberman J.A., Gilmore J.H. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 2001, 47:27-36.
179. van Noort J.M., Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog Brain Res 2009, 175:139-148.
180. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
181. Waldorf K.M.A., Persing D., Novy M.J., Sadowsky D.W., Gravett M.G. Pre-treatment with Toll-like receptor 4 antagonist inhibits lipopolysaccharide-induced preterm uterine contractility, cytokines, and prostaglandins in rhesus monkeys. Reprod Sci 2008, 15:121-127.
182. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008, 4:189-216.
183. Wang X., Rousset C.I., Hagberg H., Mallard C. Polysaccharide-induced inflammation and perinatal brain injury. Semin Fetal Neonatal Med 2006, 11:343-353.
184. Wells P.G., McCallum G.P., Chen C.S., Henderson J.T., Lee C.J., Perstin J., et al. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol Sci 2009, 108:4-18.
185. Wolff A.R., Cheyne K.R., Bilkey D.K. Behavioural deficits associated with maternal immune activation in the rat model of schizophrenia. Behav Brain Res 2011, 225:382-387.
186. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009, 38:396-406.
187. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 1998, 155:1661-1670.
188. Wright P., Takei N., Rifkin L., Murray R.M. Maternal influenza, obstetric complications, and schizophrenia. Am J Psychiatry 1995, 152:1714-1720.
189. Xie F., Hu Y., Speert D.P., Turvey S.E., Peng G., Money D.M., et al. Toxaemia Study Group. Toll-like receptor gene polymorphisms and preeclampsia risk: a case-control study and data synthesis. Hypertens Pregnancy 2010, 29:390-398.
190. Xu D.X., Chen Y.H., Wang H., Zhao L., Wang J.P., Wei W. Tumor necrosis factor alpha partially contributes to lipopolysaccharide-induced intra-uterine fetal growth restriction and skeletal development retardation in mice. Toxicol Lett 2006, 163:20-29.
191. Yamamoto M., Takeda K., Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004, 40:861-868.
192. Yang Z.W., Chengappa K.N., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., et al. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol Med 1994, 24:449-455.
193. Yao J.K., Leonard S., Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30:923-934.
194. Yao L., Kan E.M., Lu J., Hao A., Dheen S.T., Kaur C., et al. Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J Neuroinflammation 2013, 10:23.
195. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995, 8:131-145.
196. Yovel G., Sirota P., Mazeh D., Shakhar G., Rosenne E., Ben-Eliyahu S. Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking. Brain Behav Immun 2000, 14:153-169.
197. Yuan T.M., Sun Y., Zhan C.Y., Yu H.M. Intrauterine infection/inflammation and perinatal brain damage: role of glial cells and Toll-like receptor signaling. J Neuroimmunol 2010, 29:16-25.
198. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258:686-688.
199. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.
200. Zhang S.Y., Herman M., Ciancanelli M.J., Pérez de Diego R., Sancho-Shimizu V., Abel L., et al. TLR3 immunity to infection in mice and humans. Curr Opin Immunol 2013, 25:19-33.
201. Zheng L.T., Hwang J., Ock J., Lee M.G., Lee W.H., Suk K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J Neurochem 2008, 107:1225-1235.
202. Zorrilla E.P., Cannon T.D., Gur R.E., Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?. Biol Psychiatry 1996, 40:825-833.
203. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 2005, 39:311-323.
204. Zuckerman L., Rehavi M., Nachman R., Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003, 28:1778-1789.